TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04157439

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Hot fermentation was applied for 10 mints Sustain pressure on trigger point was applied with thumb for 3secs hold and 2 sec release (till pain is reduced).~Self-stretches of cervical muscles (10 reps× 1set) For home plan cervical muscles stretching and postural care was guided

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Group
Description: Hot fermentation was applied for 10 mints. Integrated Neuromuscular Inhibition Technique \[sustain pressure, Post Isometric Relaxation (PIR) and SCS\]. Sustain pressure was applied on trigger points using thumb for 3 sec hold and 2 mints release (till pain is reduced).~Post isometric stretch (MET) was given with 4 repetitions (6-10sec hold). Strain counter strain was given in which upper trapezius shortened position was maintained by slight flexion, same side bending, opposite rotation and shoulder abduction for 90 sec and repeats this procedure till the pain is reduced to 3 out of 10.~Self-stretches for cervical muscles were done at the end of session to maintain the gained ranges (10 reps×1 set) For home plan cervical muscles stretching and postural care was guided
Study: NCT03143439

Intervention type: BEHAVIORAL
Intervention: Fathers Advancing Communities Together (FACT) program
Description: The FACT program offers fathers and their families responsible parenting, healthy relationship, and economic stability services and activities.
Study: NCT03576976

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Remediation
Description: Computer-based exercises targeting impairments in cognitive domains (sensory processing, processing speed, attention, working memory, memory, executive functions) are paired with verbal discussions and group-based activities to strengthen metacognition to and bridge newly learned cognitive skills to everyday life.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation
Description: Computer-based exercises targeting impairments in cognitive domains (sensory processing, processing speed, attention, working memory, memory, executive functions) are paired with verbal discussions and group-based activities to strengthen metacognition to and bridge newly learned cognitive skills to everyday life.
Study: NCT02155062

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole grain rye

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole grain wheat

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Refined cereal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Refined cereal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Refined cereal
Study: NCT02055716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulforadex

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: alpha-cyclodextrin
Study: NCT04448483

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paretic upper limb functional electric stimulation through RehaStim
Description: The stimulation will activate upper limb muscles to perform motor rehabilitation exercises for the upper limb with the help of the Gloreha Sinfonia robotic glove that will assist-as-needed hands movements. Motor intention will be detected by a BCI (Brain Computer Interface) from the non-invasive measure of brain activity by using electroencephalography.~The motor rehabilitation exercises include upper limb and hand mobilization and functional tasks, such as hand open/closing, wrist flexion/extension, and reach and grasp a cup, keep and release.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paretic upper limb functional electric stimulation through RehaStim
Description: The stimulation will activate upper limb muscles to perform motor rehabilitation exercises for the upper limb with the help of the Gloreha Sinfonia robotic glove that will assist-as-needed hands movements. Motor intention will be detected by a BCI (Brain Computer Interface) from the non-invasive measure of brain activity by using electroencephalography.~The motor rehabilitation exercises include upper limb and hand mobilization and functional tasks, such as hand open/closing, wrist flexion/extension, and reach and grasp a cup, keep and release.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive transcranial current stimulation through DC-Stimulator
Description: Non-invasive brain stimulation in the form of transcranial direct current stimulation will be provided in addition to the previous intervention.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive transcranial current stimulation through DC-Stimulator
Description: Non-invasive brain stimulation in the form of transcranial direct current stimulation will be provided in addition to the previous intervention.
Study: NCT01804621

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Newsletter
Description: Participants received a health newsletter with articles about general health articles, as well as targeted health articles (differs by condition).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Newsletter
Description: Participants received a health newsletter with articles about general health articles, as well as targeted health articles (differs by condition).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Newsletter
Description: Participants received a health newsletter with articles about general health articles, as well as targeted health articles (differs by condition).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Newsletter
Description: Participants received a health newsletter with articles about general health articles, as well as targeted health articles (differs by condition).
Study: NCT03673332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: immune-checkpoint inhibitors therapies
Description: All patients included in this study will receive approved immune-checkpoint inhibitors therapies, such as CTLA-4, PD-1, and PD-L1 inhibitors.
Study: NCT04010487

Intervention type: GENETIC
Intervention: whole exome sequencing and RNA-sequencing
Description: The specimens from adenomyosis, endometrial cancer, and eutopic endometrium will be tested by whole exome sequencing and RNA-sequencing

Intervention type: GENETIC
Intervention: whole exome sequencing and RNA-sequencing
Description: The specimens from adenomyosis, endometrial cancer, and eutopic endometrium will be tested by whole exome sequencing and RNA-sequencing
Study: NCT02076698

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AN-DBS
Description: Electrode and one multichannel stimulator surgical time: 4 to 6 hours 3 visits of adjustment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Usual treatment
Description: usual treatment of epilepsy Vagus nerve stimulation: maintained
Study: NCT02898337

Intervention type: DEVICE
Intervention: AliveCor handheld mobile ECG
Description: Specific Aim 1: independent risk factors for methadone-associated QTc interval prolongation will be determined through retrospective analysis of electronic medical records of methadone-treated patients in a narcotic treatment center. Patients will be asked to come to the Narcotic Treatment Center for one 12-lead ECG~Specific Aim 2: QTc intervals from ECGs generated by the AliveCor® heart monitor will be compared prospectively to simultaneous twelve lead ECGs for validation purposes in the methadone-treated patients in a narcotic treatment center.

Intervention type: DEVICE
Intervention: AliveCor handheld mobile ECG
Description: Specific Aim 1: independent risk factors for methadone-associated QTc interval prolongation will be determined through retrospective analysis of electronic medical records of methadone-treated patients in a narcotic treatment center. Patients will be asked to come to the Narcotic Treatment Center for one 12-lead ECG~Specific Aim 2: QTc intervals from ECGs generated by the AliveCor® heart monitor will be compared prospectively to simultaneous twelve lead ECGs for validation purposes in the methadone-treated patients in a narcotic treatment center.
Study: NCT00289471

Intervention type: OTHER
Intervention: No intervention delivered.
Description: No intervention delivered.
Study: NCT03542474

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity Endurance Exercise
Description: Treadmill exercise at 80%-85% maximum heart rate for 30 minutes a day, 3 times per week, for 6 months.
Study: NCT04449718

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: 200,000 IU on admission
Study: NCT00479609

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Transdermal testosterone therapy
Description: testosterone 1% hydroalcohol gel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo gel
Study: NCT03602482

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standing
Description: Participants will stand and complete cognitive tests.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supine
Description: Participants will complete cognitive tests while supine.
Study: NCT01372137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOX-H94
Description: Dosage form: NOX-H94 25 mg (oligonucleotide basis) Solution for Injection Strength: 14.6 mg NOX-H94 / mL Dose: 0.3 - 4.8 mg/kg single dose Route: IV infusion over 15 minutes / SC administration

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Glucose 5%
Description: Placebo
Study: NCT01007084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: 40 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol ER
Description: 120 mg twice per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pills
Description: sugar pill
Study: NCT01850875

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eye-Movement-Desensitization-Reprocessing
Study: NCT04433377

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Suprascapular nerve block
Description: A betamethasone dipropionate plus betamethasone sodium phosphate solution (6.43 mg / mL + 2.63 mg / mL; 1 mL), 0.5 % bupivacaine (2 mL) and physiological serum (2 mL) are injected with an in-plane technique using a 22 gauge 90-mm injector

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Subacromial injection
Description: A betamethasone dipropionate plus betamethasone sodium phosphate solution (6.43 mg/mL + 2.63 mg/mL; 1 mL), 2% lidocaine (2 mL) and physiological serum (2 mL) are injected with an in-plane technique using a 21 gauge 38-mm injector.
Study: NCT02417597

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Hepatitis E Vaccine (Escherichia Coli)
Description: Participants would intramuscularly receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) at 0, 1, 6 month.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Hepatitis E Vaccine (Escherichia Coli)
Description: Participants would intramuscularly receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) at 0, 1, 6 month.
Study: NCT02840097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: Active drug is provided to participants as described based on the TXA arm they are randomized to.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: Active drug is provided to participants as described based on the TXA arm they are randomized to.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline is provided to participants if randomized to this treatment arm.
Study: NCT00819611

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cogmed Working memory training
Description: 15 minutes of working memory training, 5 days a week for a period of 5 weeks

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Control version of Cogmed working memory training
Description: 15 minutes of 'sham' working memory training, 5 days a week for a period of 5 weeks
Study: NCT02665520

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: liposuction for retrieval of own stem cells from fat cells
Study: NCT02937909

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Use of wound care products from a single manufacturer
Description: The participating Healthcare Professionals will be asked to use BSN medical wound care products for the study duration
Study: NCT02577510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nerve Injection- Nerve Stimulator
Description: For the neurostimulation nerve injection technique, the initial puncture site will be located medial to the anterosuperior iliac spine, just caudal to the inguinal ligament \[7\]. The 22-gauge insulated needle will be connected to a stimulator set at a current of 1.5 mA, a pulse width of 300 ms and a frequency of 2 Hz. A paresthesia referred to the lateral aspect of the thigh at a minimal stimulatory threshold of 0.6 mA (0.3ms) will be sought prior to the injection of local anesthetic \[7\]. A total of 5cc of 2%Xylocaine will be injected for the nerve injection/anesthesia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nerve Injection - Ultrasound
Description: For the ultrasound nerve injection group, after skin disinfection, the inguinal region of patients will be scanned using a high-frequency (6 to 13 MHz) linear array transducer covered with a sterile plastic cover. An ultrasound image showing the inguinal ligament and anterior superior iliac spine (ASIS) will be obtained. Using an out-of-plane technique, a 22-gauge nerve block needle will be inserted 1-2 cm medial to ASIS. The needle will be advanced until its tip rests under the inguinal ligament, immediately ventral to the iliopsoas muscle \[6\]. A total of 5cc of 2%Xylocaine will be injected for the nerve injection/anesthesia.
Study: NCT04334031

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Biobanking with genetic analysis
Description: Patients included in the IMMINeNT cohort will be collected 7 blood samples for the research project at each revaluation visit. For patients who accepted, genetic analysis (DNA analysis) will be done on a part of those samples.
Study: NCT04203394

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Schroth Exercise Group
Description: 12 week , Exercises 1 hour, 2 times for a week with physiotherapist 20 minutes home exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home Exercise Group
Description: Home exercise 20 min at home Once, one hour to determine the Schroth program + teaching home exercises 20 minutes home exercise
Study: NCT04377308

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine
Description: Fluoxetine 20 mg to 60 mg daily given from 2 weeks to 2 months duration
Study: NCT00840229

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Triamcinolone hexacetonide
Description: 20 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone hexacetonide
Description: 1 ml (20 mg) + 6 ml Lidocaine 10 mg/ml

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone hexacetonide
Description: 1 ml (20 mg) + 6 ml Lidocaine 10 mg/ml
Study: NCT04449718

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 200,000 IU on admission
Study: NCT02128958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CF102
Description: orally q12h

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: orally q12 hours
Study: NCT03073200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Description: Administered SC
Study: NCT02961868

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Abdominal and supra-aortic trunks vascular imaging
Description: Abdominal and supra-aortic trunks vascular imaging (angiography, CT-angiography or MR-angiography) will be performed 3 years after inclusion. This imaging will be compare to initial imaging (which is a part of usual care, not an intervention added by the study) in order to assess FMD progression.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Blood sampling (genetic)
Description: A sample of blood will be taken to meet the objective of estimating the rate of genetic polymorphism that may influence disease progression or be associated with complications.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sampling (biomarkers)
Description: A sample of blood will be taken to biomarkers analysis to meet the primary objective of assessing the risk factors for progression of FMD lesions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Urine sampling
Description: A sample of urine will be taken to biomarkers analysis to meet the primary objective of assessing the risk factors for progression of FMD lesions.
Study: NCT03073200

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Administered SC
Study: NCT04384705

Intervention type: OTHER
Intervention: research specific blood sample
Description: * one blood sample before the epidemic phase~* one blood sample during epidemic phase~* one blood sample after epidemic phase
Study: NCT02277691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-536TCH tablet
Description: TAK-536TCH tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-536CCB tablet
Description: TAK-536CCB tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCTZ 12.5 mg tablet
Description: HCTZ tablets
Study: NCT03688334

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen 40 %
Description: Oxygen supplementation (40%) via Venturi mask

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Medical air (sham O2)
Description: Medical air supplementation via Venturi mask
Study: NCT01625611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: Naltrexone 100 mg titrated over one week
Study: NCT02645136

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates
Description: Pilates exercises

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PFMT and AES
Description: conventional pelvic floor muscle exercises combined with anal electrical stimulation Device: electrical stimulation (Dualpex 961 Uro®)
Study: NCT01222442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3199
Description: Single dose, oral inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3199
Description: Single dose, oral inhalation
Study: NCT02087995

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring
Description: A prescribed clinic session day for participating subjects.
Study: NCT01723579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nomegestrol acetate (NOMAC)
Description: Oral tablet with daily release of 2.5 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol (E2)
Description: Daily release of 1.5 mg
Study: NCT01222442

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Single dose, oral encapsulated tablet

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: Single dose, oral inhalation
Study: NCT02338024

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified Antiretroviral Treatment Access Study intervention
Study: NCT04334031

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SF-12 questionnaire
Description: Patients included in the IMMINeNT cohort will be asked to complete SF-12 quality of life questionnaire.
Study: NCT03284944

Intervention type: DEVICE
Intervention: Small-Volume
Description: Small-volume (2 - 3 mL soft-draw Vacutainer tubes, Beckton Dickinson) ethylenediaminetetraacetic acid (EDTA), lithium-heparin, citrate, fluoride and silica tubes.

Intervention type: DEVICE
Intervention: Standard-Volume
Description: Standard-volume (4 - 6 mL Vacutainer tubes, Beckton Dickinson) ethylenediaminetetraacetic acid (EDTA), lithium-heparin, citrate, fluoride and silica tubes.
Study: NCT00786149

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Varenicline plus Motivational Interviewing counseling
Description: Motivational Interviewing; 8 weeks of counseling
Study: NCT01449617

Intervention type: DRUG
Intervention: Aspirin plus clopidogrel
Description: Clopidogrel, will be started 48 hours before the procedure with a loading dose of of 300mg and continued at 75mg/day.~Aspirin will be given at the dose of 100-325mg/day.
Study: NCT04436289

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home Link
Description: In the Home Link intervention, a team will conduct home visits to (1) provide a structured clinical assessment; (2) reconcile medications, (3) provide psychosocial support through patient-centered counseling, and (4) assess home needs (food security). These visits will start one week after discharge and be repeated every two weeks until the participant is stabilized and ready to initiate lower intensity clinic-based services or three months have elapsed.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home Link
Description: In the Home Link intervention, a team will conduct home visits to (1) provide a structured clinical assessment; (2) reconcile medications, (3) provide psychosocial support through patient-centered counseling, and (4) assess home needs (food security). These visits will start one week after discharge and be repeated every two weeks until the participant is stabilized and ready to initiate lower intensity clinic-based services or three months have elapsed.
Study: NCT00645034

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo by mouth as a single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sildenafil
Description: sildenafil 100 mg by mouth as a single dose
Study: NCT00645359

Intervention type: PROCEDURE
Intervention: diffusion MRI
Description: Diffusion MRI involves using MRI scanning to measure water transport at the cellular level. In this study, dMRI is being used to measure the response of tumors to chemotherapy.
Study: NCT00785200

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Description: Chlorhexidine-soaked disposable cloths will be distributed each Monday, Wednesday, and Friday to each enrolled detainee for a 6-month period.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: Water-soaked disposable wash cloths identical in appearance to the CHG cloths will be distributed to enrolled detainees on every Monday, Wednesday, and Friday for a 6-month period.
Study: NCT02036177

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SCu300A IUB intrauterine device
Description: Spherical copper IUD

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: T380A IUD
Description: T-shaped copper IUD